SunTrust Banks assumed coverage on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a report issued on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $13.00 price target on the biopharmaceutical company’s stock. SunTrust Banks also issued estimates for Dicerna Pharmaceuticals’ Q4 2017 earnings at ($0.49) EPS, FY2017 earnings at ($2.59) EPS, Q1 2018 earnings at ($0.58) EPS, Q2 2018 earnings at ($0.59) EPS, Q3 2018 earnings at ($0.48) EPS, Q4 2018 earnings at ($0.40) EPS, FY2018 earnings at ($1.76) EPS, FY2019 earnings at ($1.75) EPS, FY2020 earnings at ($1.52) EPS, FY2021 earnings at ($1.51) EPS and FY2022 earnings at ($0.98) EPS.

DRNA has been the subject of a number of other reports. Zacks Investment Research lowered Dicerna Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, November 7th. Chardan Capital reiterated a neutral rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, January 16th. Evercore ISI started coverage on Dicerna Pharmaceuticals in a report on Tuesday, January 16th. They set an outperform rating and a $14.00 price target for the company. ValuEngine upgraded Dicerna Pharmaceuticals from a sell rating to a hold rating in a report on Sunday, December 31st. Finally, HC Wainwright restated a buy rating and issued a $10.00 target price (up from $6.00) on shares of Dicerna Pharmaceuticals in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $10.05.

Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at $9.75 on Monday. Dicerna Pharmaceuticals has a 1-year low of $2.43 and a 1-year high of $11.19. The company has a market capitalization of $503.51, a P/E ratio of -2.84 and a beta of 2.75.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. The business had revenue of $0.47 million for the quarter. During the same period in the previous year, the business posted ($0.68) EPS. The firm’s revenue was up 192.6% on a year-over-year basis. equities research analysts expect that Dicerna Pharmaceuticals will post -2.93 EPS for the current fiscal year.

In other news, Director Bain Capital Life Sciences Inv bought 285,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was acquired at an average cost of $7.00 per share, for a total transaction of $1,995,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 29.41% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Deschutes Portfolio Strategy LLC acquired a new position in shares of Dicerna Pharmaceuticals in the third quarter valued at $575,000. Birchview Capital LP grew its position in Dicerna Pharmaceuticals by 125.0% in the third quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 25,000 shares during the period. First Manhattan Co. bought a new stake in Dicerna Pharmaceuticals in the fourth quarter valued at $3,865,000. Vanguard Group Inc. grew its position in Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after acquiring an additional 14,517 shares during the period. Finally, Northern Trust Corp grew its position in Dicerna Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 2,094 shares during the period. Institutional investors and hedge funds own 22.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Dicerna Pharmaceuticals (DRNA) Coverage Initiated at SunTrust Banks” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/02/08/dicerna-pharmaceuticals-drna-coverage-initiated-at-suntrust-banks.html.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.